Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2009 by Maastricht University Medical Center.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

Maastricht University Medical Center

ClinicalTrials.gov Identifier:

NCT00368199

First received: August 22, 2006

Last updated: January 12, 2009

Last verified: January 2009

History of Changes

Purpose

The purpose of the study is to determine the sensitivity and specificity of transcranial duplex scanning (TCD) and single photon emission computer tomography (SPECT) in patients suspected of having Idiopathic Parkinson Disease (PD) or Atypical Parkinson Syndromes (APS) with as golden standard the clinical diagnosis after 2-year follow-up.

Condition	Phase
Parkinson's Disease Parkinsonian Syndrome Multiple System Atrophy Supranuclear Palsy, Progressive Essential Tremor Vascular Parkinsonism Drug Induced Parkinsonism	Phase 0

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Diagnostic Value Transcranial Duplex Scanning and Single Photon Emission Tomography in Patients Suspected of Having Idiopathic Parkinson Disease or Atypical Parkinson Syndromes

Resource links provided by NLM:

Genetics Home Reference related topics: essential tremor multiple system atrophy Parkinson disease Perry syndrome progressive supranuclear palsy

MedlinePlus related topics: Nuclear Scans Paralysis Parkinson's Disease Progressive Supranuclear Palsy Tremor

U.S. FDA Resources

Further study details as provided by Maastricht University Medical Center:

Biospecimen Retention: None Retained

no biocpsicmens

Estimated Enrollment:	250
Study Start Date:	September 2006
Estimated Study Completion Date:	September 2010

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

250 Patients with unclear parkinsonism at the outpatient clinic

Criteria

Inclusion Criteria:

Patients with unclear parkinsonism at the outpatient clinic

Exclusion Criteria:

Known diagnosis at presentation
Life expectation of less than two years because of a non neurological disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00368199

Locations

Netherlands
Vlaar AMM, resident in neurology
Maastricht, PO box 5800, Netherlands, 6202 AZ

Sponsors and Collaborators

Maastricht University Medical Center

Investigators

Principal Investigator:

Wim EJ Weber, MD PhD

Maastricht University Medical Center

More Information

Additional Information:

Sponsorship This link exits the ClinicalTrials.gov site

Homepage of Department of Neurology University Hospital Maastricht This link exits the ClinicalTrials.gov site

Publications:

Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999 Sep 22;53(5):1026-31.

Becker G, Struck M, Bogdahn U, Becker T. Echogenicity of the brainstem raphe in patients with major depression. Psychiatry Res. 1994 Jun;55(2):75-84.

Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002 Jun;59(6):999-1005.

Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 1995 Jan;45(1):182-4.

Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology. 2003 Jan 14;60(1):74-7.

Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry. 2005 Mar;76(3):423-5.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Vlaar AM, Bouwmans AE, van Kroonenburgh MJ, Mess WH, Tromp SC, Wuisman PG, Kessels AG, Winogrodzka A, Weber WE. Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms. BMC Neurol. 2007 Sep 4;7:28.

Responsible Party:	AMM Vlaar, University hospital Maastricht, department of neurology
ClinicalTrials.gov Identifier:	NCT00368199 History of Changes
Other Study ID Numbers:	1-Vlaar
Study First Received:	August 22, 2006
Last Updated:	January 12, 2009
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Maastricht University Medical Center:

single photon emission computer tomography (SPECT)
transcranial sonography
transcranial duplex scanning
parkinson's disease
atypical parkinson syndromes

parkinsonism
parkinsonian
diagnostic
progressive supranuclear paralysis

Additional relevant MeSH terms:

Parkinson Disease
Multiple System Atrophy
Shy-Drager Syndrome
Supranuclear Palsy, Progressive
Tremor
Parkinsonian Disorders
Parkinson Disease, Secondary
Essential Tremor
Atrophy
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

Primary Dysautonomias
Autonomic Nervous System Diseases
Hypotension
Vascular Diseases
Cardiovascular Diseases
Ophthalmoplegia
Ocular Motility Disorders
Cranial Nerve Diseases
Tauopathies
Paralysis
Neurologic Manifestations
Eye Diseases
Signs and Symptoms
Dyskinesias
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on May 16, 2013

To Top